Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | XENE |
---|---|---|
09:32 ET | 619 | 42.8 |
09:41 ET | 200 | 42.575 |
09:43 ET | 300 | 41.99 |
09:50 ET | 200 | 42.07 |
09:52 ET | 1608 | 41.975 |
09:54 ET | 100 | 41.93 |
09:56 ET | 100 | 41.97 |
10:01 ET | 318 | 41.97 |
10:03 ET | 400 | 42.04 |
10:12 ET | 100 | 42.08 |
10:15 ET | 1095 | 42.38 |
10:17 ET | 791 | 42.32 |
10:19 ET | 1045 | 42.365 |
10:21 ET | 400 | 42.425 |
10:26 ET | 200 | 42.395 |
10:30 ET | 200 | 42.51 |
10:32 ET | 500 | 42.515 |
10:33 ET | 374 | 42.58 |
10:35 ET | 900 | 42.55 |
10:46 ET | 700 | 42.6 |
10:50 ET | 1498 | 42.71 |
10:55 ET | 300 | 42.665 |
10:57 ET | 100 | 42.615 |
11:04 ET | 100 | 42.585 |
11:13 ET | 100 | 42.6 |
11:15 ET | 699 | 42.67 |
11:20 ET | 500 | 42.68 |
11:22 ET | 100 | 42.73 |
11:31 ET | 208 | 42.67 |
11:36 ET | 936 | 42.79 |
11:38 ET | 100 | 42.79 |
11:44 ET | 529 | 42.785 |
11:45 ET | 400 | 42.74 |
11:47 ET | 600 | 42.55 |
11:54 ET | 100 | 42.54 |
11:58 ET | 100 | 42.55 |
12:02 ET | 200 | 42.575 |
12:03 ET | 200 | 42.53 |
12:12 ET | 400 | 42.51 |
12:16 ET | 1724 | 42.56 |
12:18 ET | 100 | 42.6 |
12:20 ET | 800 | 42.62 |
12:27 ET | 234 | 42.6 |
12:30 ET | 200 | 42.61 |
12:32 ET | 521 | 42.6 |
12:34 ET | 200 | 42.565 |
12:38 ET | 100 | 42.49 |
12:39 ET | 434 | 42.46 |
12:41 ET | 1100 | 42.31 |
12:43 ET | 1004 | 42.38 |
12:45 ET | 400 | 42.43 |
12:56 ET | 100 | 42.425 |
12:57 ET | 100 | 42.385 |
12:59 ET | 100 | 42.37 |
01:01 ET | 892 | 42.47 |
01:06 ET | 600 | 42.49 |
01:08 ET | 300 | 42.48 |
01:10 ET | 617 | 42.565 |
01:14 ET | 100 | 42.6 |
01:15 ET | 300 | 42.565 |
01:19 ET | 550 | 42.59 |
01:21 ET | 600 | 42.66 |
01:26 ET | 200 | 42.68 |
01:32 ET | 100 | 42.69 |
01:35 ET | 1100 | 42.77 |
01:37 ET | 200 | 42.845 |
01:39 ET | 900 | 42.87 |
01:42 ET | 1000 | 42.77 |
01:44 ET | 2009 | 42.53 |
01:50 ET | 739 | 42.455 |
01:55 ET | 122 | 42.51 |
02:02 ET | 300 | 42.505 |
02:06 ET | 200 | 42.54 |
02:08 ET | 1120 | 42.57 |
02:09 ET | 200 | 42.66 |
02:11 ET | 1849 | 42.85 |
02:13 ET | 100 | 42.74 |
02:15 ET | 100 | 42.73 |
02:18 ET | 2511 | 42.76 |
02:20 ET | 950 | 42.8 |
02:24 ET | 100 | 42.775 |
02:26 ET | 200 | 42.775 |
02:27 ET | 400 | 42.78 |
02:29 ET | 2072 | 42.77 |
02:31 ET | 1250 | 42.85 |
02:36 ET | 400 | 42.84 |
02:40 ET | 510 | 42.77 |
02:42 ET | 100 | 42.86 |
02:45 ET | 100 | 42.78 |
02:47 ET | 490 | 42.9 |
02:49 ET | 100 | 42.86 |
02:51 ET | 607 | 42.88 |
02:54 ET | 100 | 42.9 |
02:56 ET | 1280 | 42.78 |
03:02 ET | 200 | 42.76 |
03:03 ET | 100 | 42.785 |
03:05 ET | 300 | 42.77 |
03:07 ET | 200 | 42.82 |
03:09 ET | 200 | 42.79 |
03:12 ET | 400 | 42.77 |
03:14 ET | 520 | 42.775 |
03:18 ET | 308 | 42.77 |
03:20 ET | 200 | 42.82 |
03:25 ET | 836 | 42.81 |
03:27 ET | 200 | 42.82 |
03:30 ET | 2000 | 42.74 |
03:32 ET | 726 | 42.81 |
03:34 ET | 200 | 42.8 |
03:36 ET | 100 | 42.83 |
03:38 ET | 300 | 42.8 |
03:39 ET | 200 | 42.78 |
03:41 ET | 1100 | 42.785 |
03:43 ET | 2994 | 42.8945 |
03:45 ET | 646 | 42.88 |
03:48 ET | 1100 | 42.915 |
03:50 ET | 1000 | 42.91 |
03:52 ET | 1381 | 42.81 |
03:54 ET | 3843 | 42.94 |
03:56 ET | 3082 | 42.78 |
03:57 ET | 3329 | 42.87 |
03:59 ET | 13243 | 43 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Xenon Pharmaceuticals Inc | 3.2B | -15.8x | --- |
Summit Therapeutics Inc | 3.3B | -2.6x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Janux Therapeutics Inc | 3.0B | -46.5x | --- |
IDEAYA Biosciences Inc | 3.1B | -21.1x | --- |
Iovance Biotherapeutics Inc | 3.5B | -6.8x | --- |
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.2B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 75.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.26 |
EPS | $-2.73 |
Book Value | $12.31 |
P/E Ratio | -15.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.